^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Jiataile (sacituzumab tirumotecan)

    i
    Other names: MK-2870, SKB 264, SKB264, sac-TMT, SKB-264, MK2870, MK 2870
    Company:
    Merck (MSD), Sichuan Kelun Pharma
    Drug class:
    Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    16h
    SKB264-ANLO: Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, China Medical University, China
    New P2 trial
    |
    Focus V (anlotinib) • Jiataile (sacituzumab tirumotecan)
    3d
    TroFuse-015: A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (clinicaltrials.gov)
    P3, N=450, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    paclitaxel • docetaxel • irinotecan • Lonsurf (trifluridine/tipiracil) • Jiataile (sacituzumab tirumotecan)
    6d
    A Phase II Exploratory Study of Sacituzumab Tirumotecan (Sac-TMT/SKB264) in Combination with Bevacizumab for Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Open-Label, Multicenter Clinical Trial (ChiCTR2500108816)
    P2, N=38, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical UniversitynThe First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliate | Initiation date: Sep 2025 --> Feb 2026
    Trial initiation date
    |
    Avastin (bevacizumab) • Trodelvy (sacituzumab govitecan-hziy) • Jiataile (sacituzumab tirumotecan)
    6d
    Switching to Sacituzumab Govitecan Combined Toripalimab in TNBC Patients:Tumor Non-Response After the First Stage of NC A Single-Arm Clinical Study to Explore the Efficacy and Safety (ChiCTR2500112392)
    P=N/A, N=31, Not yet recruiting, Fujian Medical University Union Hospital; Fujian Medical University Union Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Loqtorzi (toripalimab-tpzi) • Trodelvy (sacituzumab govitecan-hziy) • Jiataile (sacituzumab tirumotecan)
    6d
    The Pilot Study on Sacituzumab tirumotecan (SKB264) for the Treatment of Recurrent Adamantinomatous Craniopharyngioma (ACP) (ChiCTR2500111542)
    P=N/A, N=12, Not yet recruiting, Xuanwu Hospital, Capital Medical University; Xuanwu Hospital, Capital Medical University
    New trial
    |
    Jiataile (sacituzumab tirumotecan)
    6d
    Clinical Study of ctDNA Dynamic Monitoring in Sacituzumab tirumotecan for EGFR-Mutated Non-Squamous NSCLC After EGFR-TKI Failure (ChiCTR2600115950)
    P4, N=30, Not yet recruiting, Shaanxi Provincial Cancer Hospital; Shaanxi Provincial Cancer Hospital
    New P4 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Jiataile (sacituzumab tirumotecan)
    6d
    A Single-arm, Single-center Phase II Clinical Study of Sacituzumab tirumotecan Combined with Anlotinib in the Second-line Treatment of Patients with Advanced Gastric Cancer (ChiCTR2500112073)
    P4, N=33, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New P4 trial
    |
    Focus V (anlotinib) • Jiataile (sacituzumab tirumotecan)
    6d
    Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer (ChiCTR2500112194)
    P4, N=30, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New P4 trial
    |
    Avastin (bevacizumab) • Jiataile (sacituzumab tirumotecan)
    6d
    Sintilimab Combined with Sacituzumab tirumotecan in Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Single-Arm, Single-Center, Phase II Clinical Study (ChiCTR2500111980)
    P4, N=49, Not yet recruiting, Tangdu Hospital, Fourth Military Medical University; Tangdu Hospital, Fourth Military Medical University
    New P4 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tyvyt (sintilimab) • Jiataile (sacituzumab tirumotecan)
    6d
    Phase II Clinical Trial of Sacituzumab tirumotecan Combined with Cadonilimab as Second-Line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Single-Center Study (ChiCTR2600116847)
    P2, N=33, Not yet recruiting, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New P2 trial
    |
    Kaitanni (cadonilimab) • Jiataile (sacituzumab tirumotecan)
    6d
    A Phase II, Prospective, Single-Arm, Multicenter, Open-Label Study of Sacituzumab tirumotecan in Combination with Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Locally Advanced Cervical Cancer (ChiCTR2600116767)
    P2, N=25, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 expression
    |
    Jiataile (sacituzumab tirumotecan) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    6d
    A single-arm, multicenter, phase II clinical trial on sacituzumab tirumotecan with toripalimab in neoadjuvant therapy for triple-negative breast cancer (ChiCTR2600116626)
    P2, N=34, Not yet recruiting, Jiangxi Cancer Hospital; Jiangxi Cancer Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative
    |
    Loqtorzi (toripalimab-tpzi) • Jiataile (sacituzumab tirumotecan)